AR and prostate carcinoma: The analyses described herein are the largest report to date examining the impact of a broad range of androgen‐targeting therapies that included androgen receptor inhibitors and androgen synthesis inhibitors on neurodegenerative disease incidence in a cohort of men with prostate cancer.